Vericel Corp
NASDAQ:VCEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vericel Corp
NASDAQ:VCEL
|
US |
|
Petrolia S.E
F:0PE
|
CY |
Intrinsic Value
The intrinsic value of Vericel Corp (VCEL) under the Base Case is 47.581 USD per share.
Compared with the current market price of 40.305 USD, the stock appears
Undervalued by 15% .
The intrinsic value is calculated using the DCF method. The model assumes net margin rises from 6% last year to 7.9% by 2033, higher than in any of the last six years. If net margin stayed at its five-year average of -1.2%, the estimate would be about $42. The value of the years after 2033 is tied to revenue, so margins count only until then.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Vericel Does
Vericel Corp makes and sells specialty cell-therapy products for difficult orthopedic and burn injuries. Its main products are used by surgeons and hospitals to treat damaged knee cartilage and severe burns, where standard treatments may not work as well. The company focuses on very specific medical problems instead of broad drug categories.
- Headquarters
- United States of America US
- Employees
- 398
- IPO date
- Feb 4, 1997
Latest Earnings Call
- EPS
- $0.04
- Expected
- −$0.04
- Surprise
- +200.0%
- Stock, day of the call
- +2.1%
Revenue & Expenses Breakdown
Vericel Corp
Earnings Waterfall
Vericel Corp
The intrinsic value for Vericel Corp (VCEL) under the Base Case is 47.581 USD.
Compared with the current market price of 40.305 USD, the stock appears Undervalued by 15% .